Digital therapeutics will need to meet quality standards like those set by conventional drugs . Although such novel treatments are gaining approval by the US Food & Drug Administration , another requirement is compliance with quality standards from the United States Pharmacopeia ( USP ) , which will be challenging . USP uses four criteria for drug quality which are Identity, Strength, Purity and Performance. The USP is looking to introduce standards that will enable doctors to confidently use the new treatments , said Stefano Piervincenzi , CEO of Roche . Joris Van Dam , head of digital therapeutics at Novartis , said early software testing could be likened to preclinical studies for drugs .
Digital therapeutics will need to meet quality standards like those set by conventional drugs . Although such novel treatments are gaining approval by the US Food & Drug Administration , another requirement is compliance with quality standards from the United States Pharmacopeia ( USP ) , which will be challenging . The USP is looking to introduce standards that will enable doctors to confidently use the new treatments , said Stefano Piervincenzi , CEO of Roche . Joris Van Dam , head of digital therapeutics at Novartis , said early software testing could be likened to preclinical studies for drugs .